AbCellera is a technology company that is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.
Notable Press Mentions
AbCellera to make C$701 million co-investment in Canada
How AbCellera helps partners propel their antibody therapies to the clinic
AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact
Regeneron advances first program from AbCellera collaboration into further preclinical development
A year after embarking on a new HQ and manufacturing site, AbCellera starts second phase of its buildout
Versant biotechs hand AbCellera antibody discovery wish list as part of multiyear deal with the VC shop